// App-Quantinova.ai

7508 : Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508).

Researchers

Presenter

  • Chandra Prakash Belani

Principal Investigators

  • Suzanne Eleanor Dahlberg

  • Charles M. Rudin

  • Martin Fleisher

  • Helen X. Chen

  • Naoko Takebe

  • Suresh S Ramalingam

  • Joan H. Schiller

Medical Centers

  • Penn State Cancer Institute, Hershey, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • Investigational Drug Branch, Cancer Therapy Evaluation Program, Rockville, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • National Cancer Institute, Bethesda, MD

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cixutumumab

  • Vismodegib

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT00887159

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved